Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia

• DOI: 10.1002/hon.2925
• Publication Date: 2021-09-09T14:43:15Z
• Authors: Kimberley Doucette; Mary‐Elizabeth Pe...; Lacey Williams; Adrese Kandahari; Allison Taylor; Shuqi Wang; Jaeil Ahn; Judith E. Karp; Catherine Lai
• Keywords: Hypoalbuminemia; Serum Albumin

Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity mortality several malignancies. We evaluated the relationship between baseline serum albumin levels on treatment-related complications, as well short-term overall survival (OS) 756 newly diagnosed AML conducted retrospective multicenter study examine complications OS according pretreatment levels: normal ≥3.5 g/dl, marked hypoalbuminemia <2.5 2.5-3.4 g/dl. In an adjusted multivariate analysis, lower was independently associated with higher number grade ≥3 when adjusting for age, secondary AML, sex intensive treatment. When comparing markedly low levels, estimated mean increases by factor 1.35. Patients who had 30 day-mortality rate 4.8%, which significantly compared patients (16.5%) (33.9%; p < 0.01). Similarly, 60-day group (24.0%) (45%) (8.3%; have increased mortality, suggesting that pre-treatment important independent prognostic marker.